Psykey, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CEOS research report →
Companywww.psykeyworld.com
Psykey, Inc. engages in the research, development, and commercialization of entheogenic, adaptogenic, and nootropic ingredients and formulations for its functional product lines to improve and optimize life. The company also engages in the development of technologies for the composition, bioavailability, and targeted delivery of entheogen-based therapeutics for the psychedelic market.
- CEO
- Michael Maher
- IPO
- 2006
- Employees
- 6
- HQ
- Toronto, ON, CA
Price Chart
Valuation
- Market Cap
- $97.62K
- P/E
- 0.75
- P/S
- 0.00
- P/B
- 1.24
- EV/EBITDA
- 0.23
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 733.40%
- ROIC
- -104.59%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $3.12M · 990.68%
- EPS
- $0.01 · 1010.00%
- Op Income
- $-1,958,172
- FCF YoY
- -100.00%
Performance & Tape
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.00
- Beta
- 0.34
- Avg Volume
- 136.36K
Get TickerSpark's AI analysis on CEOS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CEOS Coverage
We haven't published any research on CEOS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CEOS Report →